{"id":80073,"date":"2025-09-17T14:10:40","date_gmt":"2025-09-17T11:10:40","guid":{"rendered":"https:\/\/gulftech-news.com\/en\/?p=80073"},"modified":"2025-09-17T14:10:42","modified_gmt":"2025-09-17T11:10:42","slug":"eu-approval-makes-novo-nordisks-oral-semaglutide-the-first-and-only-oral-glp-1-ra-to-reduce-cardiovascular-death-heart-attack-and-stroke","status":"publish","type":"post","link":"https:\/\/gulftech-news.com\/en\/2025\/09\/17\/eu-approval-makes-novo-nordisks-oral-semaglutide-the-first-and-only-oral-glp-1-ra-to-reduce-cardiovascular-death-heart-attack-and-stroke\/","title":{"rendered":"EU approval makes Novo Nordisk\u2019s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke"},"content":{"rendered":"\n

Oral semaglutide (Rybelsus\u00ae) is now the first and only oral GLP-1 RA approved for type 2 diabetes, with proven cardiovascular benefits1<\/strong><\/p>\n\n\n\n


This approval is based on results from the SOUL clinical trial, where oral semaglutide (Rybelsus\u00ae) reduced cardiovascular death, heart attack and stroke by 14% versus placebo, when added to standard of care, in adults with type 2 diabetes at high cardiovascular risk1<\/p>\n\n\n\n


In addition, new results from SOUL will be presented at one of the largest diabetes conferences (EASD) later this week, showing that oral semaglutide significantly reduced hospitalisations compared with placebo2<\/p>\n\n\n\n

Novo Nordisk today announced that the European Medicines Agency\u2019s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved an update to the Rybelsus\u00ae (oral semaglutide) label to reflect the cardiovascular benefits seen in the SOUL trial. SOUL was a phase 3b trial carried out to evaluate the effect of Rybelsus\u00ae on cardiovascular outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) and\/or chronic kidney disease (CKD)1. <\/p>\n\n\n\n

Rybelsus\u00ae is now the first and only oral glucagon-like peptide 1 receptor agonist (GLP-1 RA) \u2013 mimicking a natural hormone in your body that helps regulate blood sugar, appetite, and digestion \u2013 available in the EU for type 2 diabetes with a proven cardiovascular benefit1.<\/p>\n\n\n\n


\u201cHeart problems are the leading cause of disability and death for people living with type 2 diabetes. Therefore, treatments that also address heart problems are key to improving not only health outcomes, but also quality of life \u2013 and this approval will help do just that,\u201d said Emil Kongsh\u00f8j Larsen, executive vice president, International Operations at Novo Nordisk. \u201cThis milestone makes semaglutide the only oral GLP-1 RA with proven blood glucose and body weight reduction, as well as cardiovascular benefits.\u201d
New results from the SOUL trial will be shared later this week at the European Association for the Study of Diabetes (EASD) 2025 Annual Meeting, 15\u201319 September. <\/p>\n\n\n\n

These include findings that treatment with oral semaglutide significantly reduced hospitalisations related to serious adverse events compared with placebo2. Additional SOUL results will be presented at the same
CVR no: 24 25 67 90
ate of approval: September
meeting, which highlight that the cardiovascular benefits of oral semaglutide were consistent regardless of body mass index (BMI) and body weight of participants3.<\/p>\n\n\n\n


In the US, a decision is expected later this year for a label extension for the cardiovascular indication for Rybelsus\u00ae. Novo Nordisk has also submitted an application in the US for a oncedaily 25 mg oral formulation of semaglutide (Wegovy\u00ae in a pill) in adults living with obesity or overweight and cardiovascular disease. A decision is expected at the turn of this year, and if approved, Wegovy\u00ae would become the first oral GLP-1 RA indicated for chronic weight management.<\/p>\n\n\n\n


Rybelsus\u00ae is the first and only oral GLP-1 RA approved for the treatment of type 2 diabetes, following its launch in 2019. It is supported by a strong clinical and real-world evidence base, demonstrating superior blood glucose reduction and body weight reduction versus multiple comparators, as well as an established safety profile in people with type 2 diabetes4-8.<\/p>\n","protected":false},"excerpt":{"rendered":"

Oral semaglutide (Rybelsus\u00ae) is now the first and only oral GLP-1 RA approved for type 2 diabetes, with proven cardiovascular benefits1 This approval is based on results from the SOUL clinical trial, where oral semaglutide (Rybelsus\u00ae) reduced cardiovascular death, heart attack and stroke by 14% versus placebo, when added to standard of care, in adults …<\/p>\n","protected":false},"author":2,"featured_media":80074,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[644],"tags":[3142,3695],"class_list":["post-80073","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-communications-technology","tag-novo-nordisk","tag-oral-glp-1-ra"],"yoast_head":"\nEU approval makes Novo Nordisk\u2019s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke - Gulf Tech News<\/title>\n<meta name=\"description\" content=\"EU approval makes Novo Nordisk\u2019s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/gulftech-news.com\/en\/2025\/09\/17\/eu-approval-makes-novo-nordisks-oral-semaglutide-the-first-and-only-oral-glp-1-ra-to-reduce-cardiovascular-death-heart-attack-and-stroke\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EU approval makes Novo Nordisk\u2019s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke - Gulf Tech News\" \/>\n<meta property=\"og:description\" content=\"EU approval makes Novo Nordisk\u2019s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke\" \/>\n<meta property=\"og:url\" content=\"https:\/\/gulftech-news.com\/en\/2025\/09\/17\/eu-approval-makes-novo-nordisks-oral-semaglutide-the-first-and-only-oral-glp-1-ra-to-reduce-cardiovascular-death-heart-attack-and-stroke\/\" \/>\n<meta property=\"og:site_name\" content=\"Gulf Tech News\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-17T11:10:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-17T11:10:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2025\/09\/Novo-Nordisk.jpeg?v=1758107426\" \/>\n\t<meta property=\"og:image:width\" content=\"1031\" \/>\n\t<meta property=\"og:image:height\" content=\"729\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"bessan helmi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"bessan helmi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/gulftech-news.com\/en\/2025\/09\/17\/eu-approval-makes-novo-nordisks-oral-semaglutide-the-first-and-only-oral-glp-1-ra-to-reduce-cardiovascular-death-heart-attack-and-stroke\/\",\"url\":\"https:\/\/gulftech-news.com\/en\/2025\/09\/17\/eu-approval-makes-novo-nordisks-oral-semaglutide-the-first-and-only-oral-glp-1-ra-to-reduce-cardiovascular-death-heart-attack-and-stroke\/\",\"name\":\"EU approval makes Novo Nordisk\u2019s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke - Gulf Tech News\",\"isPartOf\":{\"@id\":\"https:\/\/gulftech-news.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/gulftech-news.com\/en\/2025\/09\/17\/eu-approval-makes-novo-nordisks-oral-semaglutide-the-first-and-only-oral-glp-1-ra-to-reduce-cardiovascular-death-heart-attack-and-stroke\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/gulftech-news.com\/en\/2025\/09\/17\/eu-approval-makes-novo-nordisks-oral-semaglutide-the-first-and-only-oral-glp-1-ra-to-reduce-cardiovascular-death-heart-attack-and-stroke\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2025\/09\/Novo-Nordisk.jpeg?v=1758107426\",\"datePublished\":\"2025-09-17T11:10:40+00:00\",\"dateModified\":\"2025-09-17T11:10:42+00:00\",\"author\":{\"@id\":\"https:\/\/gulftech-news.com\/en\/#\/schema\/person\/c033626e357b2f7e127eac0570ddc05c\"},\"description\":\"EU approval makes Novo Nordisk\u2019s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke\",\"breadcrumb\":{\"@id\":\"https:\/\/gulftech-news.com\/en\/2025\/09\/17\/eu-approval-makes-novo-nordisks-oral-semaglutide-the-first-and-only-oral-glp-1-ra-to-reduce-cardiovascular-death-heart-attack-and-stroke\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/gulftech-news.com\/en\/2025\/09\/17\/eu-approval-makes-novo-nordisks-oral-semaglutide-the-first-and-only-oral-glp-1-ra-to-reduce-cardiovascular-death-heart-attack-and-stroke\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/gulftech-news.com\/en\/2025\/09\/17\/eu-approval-makes-novo-nordisks-oral-semaglutide-the-first-and-only-oral-glp-1-ra-to-reduce-cardiovascular-death-heart-attack-and-stroke\/#primaryimage\",\"url\":\"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2025\/09\/Novo-Nordisk.jpeg?v=1758107426\",\"contentUrl\":\"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2025\/09\/Novo-Nordisk.jpeg?v=1758107426\",\"width\":1031,\"height\":729,\"caption\":\"EU approval makes Novo Nordisk\u2019s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/gulftech-news.com\/en\/2025\/09\/17\/eu-approval-makes-novo-nordisks-oral-semaglutide-the-first-and-only-oral-glp-1-ra-to-reduce-cardiovascular-death-heart-attack-and-stroke\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/gulftech-news.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EU approval makes Novo Nordisk\u2019s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/gulftech-news.com\/en\/#website\",\"url\":\"https:\/\/gulftech-news.com\/en\/\",\"name\":\"Gulf Tech News\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/gulftech-news.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/gulftech-news.com\/en\/#\/schema\/person\/c033626e357b2f7e127eac0570ddc05c\",\"name\":\"bessan helmi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/gulftech-news.com\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bb1e09a6f094e0fa605073926f8ad9eb228a8b0aacd381fda782c562612428cf?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bb1e09a6f094e0fa605073926f8ad9eb228a8b0aacd381fda782c562612428cf?s=96&d=mm&r=g\",\"caption\":\"bessan helmi\"},\"url\":\"https:\/\/gulftech-news.com\/en\/author\/bessan-helmi\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EU approval makes Novo Nordisk\u2019s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke - Gulf Tech News","description":"EU approval makes Novo Nordisk\u2019s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/gulftech-news.com\/en\/2025\/09\/17\/eu-approval-makes-novo-nordisks-oral-semaglutide-the-first-and-only-oral-glp-1-ra-to-reduce-cardiovascular-death-heart-attack-and-stroke\/","og_locale":"en_US","og_type":"article","og_title":"EU approval makes Novo Nordisk\u2019s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke - Gulf Tech News","og_description":"EU approval makes Novo Nordisk\u2019s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke","og_url":"https:\/\/gulftech-news.com\/en\/2025\/09\/17\/eu-approval-makes-novo-nordisks-oral-semaglutide-the-first-and-only-oral-glp-1-ra-to-reduce-cardiovascular-death-heart-attack-and-stroke\/","og_site_name":"Gulf Tech News","article_published_time":"2025-09-17T11:10:40+00:00","article_modified_time":"2025-09-17T11:10:42+00:00","og_image":[{"width":1031,"height":729,"url":"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2025\/09\/Novo-Nordisk.jpeg?v=1758107426","type":"image\/jpeg"}],"author":"bessan helmi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"bessan helmi","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/gulftech-news.com\/en\/2025\/09\/17\/eu-approval-makes-novo-nordisks-oral-semaglutide-the-first-and-only-oral-glp-1-ra-to-reduce-cardiovascular-death-heart-attack-and-stroke\/","url":"https:\/\/gulftech-news.com\/en\/2025\/09\/17\/eu-approval-makes-novo-nordisks-oral-semaglutide-the-first-and-only-oral-glp-1-ra-to-reduce-cardiovascular-death-heart-attack-and-stroke\/","name":"EU approval makes Novo Nordisk\u2019s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke - Gulf Tech News","isPartOf":{"@id":"https:\/\/gulftech-news.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/gulftech-news.com\/en\/2025\/09\/17\/eu-approval-makes-novo-nordisks-oral-semaglutide-the-first-and-only-oral-glp-1-ra-to-reduce-cardiovascular-death-heart-attack-and-stroke\/#primaryimage"},"image":{"@id":"https:\/\/gulftech-news.com\/en\/2025\/09\/17\/eu-approval-makes-novo-nordisks-oral-semaglutide-the-first-and-only-oral-glp-1-ra-to-reduce-cardiovascular-death-heart-attack-and-stroke\/#primaryimage"},"thumbnailUrl":"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2025\/09\/Novo-Nordisk.jpeg?v=1758107426","datePublished":"2025-09-17T11:10:40+00:00","dateModified":"2025-09-17T11:10:42+00:00","author":{"@id":"https:\/\/gulftech-news.com\/en\/#\/schema\/person\/c033626e357b2f7e127eac0570ddc05c"},"description":"EU approval makes Novo Nordisk\u2019s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke","breadcrumb":{"@id":"https:\/\/gulftech-news.com\/en\/2025\/09\/17\/eu-approval-makes-novo-nordisks-oral-semaglutide-the-first-and-only-oral-glp-1-ra-to-reduce-cardiovascular-death-heart-attack-and-stroke\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/gulftech-news.com\/en\/2025\/09\/17\/eu-approval-makes-novo-nordisks-oral-semaglutide-the-first-and-only-oral-glp-1-ra-to-reduce-cardiovascular-death-heart-attack-and-stroke\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/gulftech-news.com\/en\/2025\/09\/17\/eu-approval-makes-novo-nordisks-oral-semaglutide-the-first-and-only-oral-glp-1-ra-to-reduce-cardiovascular-death-heart-attack-and-stroke\/#primaryimage","url":"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2025\/09\/Novo-Nordisk.jpeg?v=1758107426","contentUrl":"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2025\/09\/Novo-Nordisk.jpeg?v=1758107426","width":1031,"height":729,"caption":"EU approval makes Novo Nordisk\u2019s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke"},{"@type":"BreadcrumbList","@id":"https:\/\/gulftech-news.com\/en\/2025\/09\/17\/eu-approval-makes-novo-nordisks-oral-semaglutide-the-first-and-only-oral-glp-1-ra-to-reduce-cardiovascular-death-heart-attack-and-stroke\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/gulftech-news.com\/en\/"},{"@type":"ListItem","position":2,"name":"EU approval makes Novo Nordisk\u2019s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke"}]},{"@type":"WebSite","@id":"https:\/\/gulftech-news.com\/en\/#website","url":"https:\/\/gulftech-news.com\/en\/","name":"Gulf Tech News","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/gulftech-news.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/gulftech-news.com\/en\/#\/schema\/person\/c033626e357b2f7e127eac0570ddc05c","name":"bessan helmi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/gulftech-news.com\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bb1e09a6f094e0fa605073926f8ad9eb228a8b0aacd381fda782c562612428cf?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bb1e09a6f094e0fa605073926f8ad9eb228a8b0aacd381fda782c562612428cf?s=96&d=mm&r=g","caption":"bessan helmi"},"url":"https:\/\/gulftech-news.com\/en\/author\/bessan-helmi\/"}]}},"_links":{"self":[{"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/posts\/80073","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/comments?post=80073"}],"version-history":[{"count":1,"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/posts\/80073\/revisions"}],"predecessor-version":[{"id":80075,"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/posts\/80073\/revisions\/80075"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/media\/80074"}],"wp:attachment":[{"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/media?parent=80073"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/categories?post=80073"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/tags?post=80073"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}